🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 21 Manchester 8 Birmingham 7 Leeds 7 Cambridge 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London21 Manchester8 Birmingham7 Leeds7 Cambridge5
All 47 cities
Target enrolment
to
21 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
London, Nottingham, Oxford
2026-05-11
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565Immune Thrombocytopenia
Incyte Corporation
Phase 2
56
Cottingham, London, Plymouth
2025-12-29
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
Incyte Corporation
Phase 3
466
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton
2025-12-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
Incyte Corporation
Phase 3
250
Croydon, London, Sheffield, Walsall
2025-11-13
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
Incyte Corporation
Phase 2
160
London, Manchester Greater
2025-11-12
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
Incyte Corporation
Phase 3
9
Cardiff, Glasgow, Leeds, Leicester, London
2025-06-04
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
Incyte Corporation
Phase 3
600
Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford
2025-02-28
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
Incyte Corporation
Phase 3
240
Bristol, Glasgow, London, Manchester, Nottingham, Plymouth
2025-01-21
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
Incyte Corporation
Phase 3
346
Dudley, Ipswich, Liverpool, London, Poole, Redhill
2024-10-10
Active, closed
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
37
London, Oxford
2024-08-08
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Active, closed
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Active, closed
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922Solid Tumors
Incyte Corporation
Phase 1
291
London, Newcastle upon Tyne
2022-07-05
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.